Finding and drugging the vulnerabilities of RAS-dependent cancers.
Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations.
Sawyers
Charles L
CL
Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. sawyersc@mskcc.org
D045744:Cell Line, Tumor; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism*
D047428:Protein Kinase Inhibitors; D018631:ras Proteins